Insights

Innovative Cancer Detection Exai Bio's cutting-edge RNA and AI-driven liquid biopsy platform offers early and accurate cancer detection, creating a compelling solution for healthcare providers and diagnostic laboratories seeking to enhance their screening capabilities.

Strong Clinical Validation Recent clinical studies demonstrating the platform's ability to detect multiple cancer types at early stages provide credibility and a foundation for partnerships with hospitals, research institutions, and pharmaceutical companies involved in oncology research and diagnostics.

Strategic Collaborations Partnerships with organizations like Quantumleaphealth highlight opportunities to expand the platform's application in treatment monitoring and clinical trials, appealing to biotech and pharma companies looking for innovative tools to improve disease management.

Venture Capital Backing Substantial Series A funding from leading investors indicates strong market confidence, which can be leveraged to open doors with institutional investors, research-focused healthcare entities, and government health programs interested in next-generation diagnostics.

Growing Market Potential The company's focus on early cancer detection aligns with current market trends favoring personalized medicine and preventative healthcare, signaling ample growth opportunities for sales of diagnostic services and platform licenses across hospitals, labs, and biotech firms.

Exai Bio Tech Stack

Exai Bio uses 8 technology products and services including Google Data Studio, Kubernetes, jsDelivr, and more. Explore Exai Bio's tech stack below.

  • Google Data Studio
    Business Intelligence
  • Kubernetes
    Containerization
  • jsDelivr
    Content Delivery Network
  • Kubeflow
    Dev Tools
  • Go
    Programming Languages
  • Node.js
    Programming Languages
  • Google Tag Manager
    Tag Management
  • Google Analytics
    Web Analytics

Media & News

Exai Bio's Email Address Formats

Exai Bio uses at least 1 format(s):
Exai Bio Email FormatsExamplePercentage
FirstL@exai.bioJohnD@exai.bio
48%
FLast@exai.bioJDoe@exai.bio
2%
FirstL@exai.bioJohnD@exai.bio
48%
FLast@exai.bioJDoe@exai.bio
2%

Frequently Asked Questions

What is Exai Bio's official website and social media links?

Minus sign iconPlus sign icon
Exai Bio's official website is exai.bio and has social profiles on LinkedInCrunchbase.

What is Exai Bio's SIC code NAICS code?

Minus sign iconPlus sign icon
Exai Bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Exai Bio have currently?

Minus sign iconPlus sign icon
As of January 2026, Exai Bio has approximately 24 employees across 1 continents, including North America. Key team members include Chief Scientific Officer: B. A.Vice President Of Engineering: A. W.Director, Clinical Laboratory Operations: R. H.. Explore Exai Bio's employee directory with LeadIQ.

What industry does Exai Bio belong to?

Minus sign iconPlus sign icon
Exai Bio operates in the Biotechnology Research industry.

What technology does Exai Bio use?

Minus sign iconPlus sign icon
Exai Bio's tech stack includes Google Data StudioKubernetesjsDelivrKubeflowGoNode.jsGoogle Tag ManagerGoogle Analytics.

What is Exai Bio's email format?

Minus sign iconPlus sign icon
Exai Bio's email format typically follows the pattern of FirstL@exai.bio. Find more Exai Bio email formats with LeadIQ.

When was Exai Bio founded?

Minus sign iconPlus sign icon
Exai Bio was founded in 2021.

Exai Bio

Biotechnology ResearchCalifornia, United States11-50 Employees

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. 

Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies.

We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another.

What We Value

Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do.

Integrity – Our thoughts and actions are true to science and to people. We do the right thing.

Openness – We recognize and respect our differences – and embrace learning from them.

Teamwork – We are team players who trust and respect each other.

Exploration – We are explorers, putting curiosity into action. 

Kindness – We are kind whenever possible – and we believe it’s always possible.

Section iconCompany Overview

Website
exai.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Exai Bio's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Exai Bio's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.